share_log

MannKind Corporation's (NASDAQ:MNKD) Institutional Investors Lost 3.9% Last Week but Have Benefitted From Longer-term Gains

MannKind Corporation's (NASDAQ:MNKD) Institutional Investors Lost 3.9% Last Week but Have Benefitted From Longer-term Gains

曼恩凯德生物医疗公司(纳斯达克:MNKD)的机构投资者上周损失了3.9%,但从长期收益中获益。
Simply Wall St ·  2024/11/28 07:44

Key Insights

主要见解

  • Significantly high institutional ownership implies MannKind's stock price is sensitive to their trading actions
  • A total of 25 investors have a majority stake in the company with 44% ownership
  • Insiders have been selling lately
  • 显著高的机构持股意味着曼恩凯德生物医疗的股票价格对其交易行为非常敏感。
  • 共有25名投资者拥有该公司的多数股份,占股44%。
  • 内部人员最近一直在卖出。

To get a sense of who is truly in control of MannKind Corporation (NASDAQ:MNKD), it is important to understand the ownership structure of the business. With 56% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

要了解谁真正控制着曼恩凯德公司(纳斯达克:MNKD),了解业务的所有权结构是非常重要的。机构以56%的股份拥有公司的最多股票。换句话说,该集团面临着最大的上行潜力(或下行风险)。

Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings value drop by 3.9% last week. However, the 87% one-year return to shareholders may have helped lessen their pain. But they would probably be wary of future losses.

投资亏损是所有股东都不喜欢的事情,尤其是那些上周其持股价值下降了3.9%的机构投资者。然而,87%的年度回报可能帮助减轻了他们的痛苦。但他们可能会对未来的损失感到警惕。

Let's delve deeper into each type of owner of MannKind, beginning with the chart below.

让我们深入探讨曼恩凯德生物医疗的每种所有者类型,从下面的图表开始。

big
NasdaqGM:MNKD Ownership Breakdown November 28th 2024
纳斯达克GM:MNKD 所有权结构 2024年11月28日

What Does The Institutional Ownership Tell Us About MannKind?

机构所有权告诉我们关于曼恩凯德生物医疗什么?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。

As you can see, institutional investors have a fair amount of stake in MannKind. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of MannKind, (below). Of course, keep in mind that there are other factors to consider, too.

正如您所看到的,机构投资者在曼恩凯德生物医疗中拥有相当数量的股份。这在职业投资者中显示出了一定的可信度。但我们不能仅仅依赖这一事实,因为机构有时也会做出错误的投资,就像其他人一样。如果两个大型机构投资者同时试图出售某只股票,股价大幅下跌并不罕见。因此,检查曼恩凯德生物医疗过去的盈利轨迹是值得的(见下文)。当然,还要记住有其他因素需要考虑。

big
NasdaqGM:MNKD Earnings and Revenue Growth November 28th 2024
纳斯达克GM:MNKD 2024年11月28日的营收和收益增长

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in MannKind. Our data shows that BlackRock, Inc. is the largest shareholder with 8.6% of shares outstanding. In comparison, the second and third largest shareholders hold about 5.7% and 3.5% of the stock. In addition, we found that Michael Castagna, the CEO has 0.8% of the shares allocated to their name.

投资者应该注意,机构实际上拥有公司的一半以上股份,因此他们可以集体拥有一定的权力。对冲基金在曼恩凯德生物医疗的股份并不多。我们的数据显示,贝莱德公司是最大股东,持有8.6%的流通股。相比之下,第二和第三大股东分别持有约5.7%和3.5%的股票。此外,我们发现首席执行官迈克尔·卡斯塔尼亚持有其名下0.8%的股份。

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

对我们的所有权数据进行更深入的研究表明,前25名股东的持股总额不到注册表的一半,表明有一个小股东的大群体,其中没有单个股东拥有多数股份。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

尽管研究公司的机构持股可以增加您的研究价值,但研究分析师的建议也是一个好习惯,以更深入地了解股票的预期表现。有相当数量的分析师关注该股,因此了解他们对未来的总体观点可能很有用。

Insider Ownership Of MannKind

曼恩凯德生物医疗的内部持股

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

虽然内部人员的具体定义可能是主观的,但几乎所有人都认为董事会成员是内部人员。公司管理层应向董事会回答问题,后者应代表股东的利益。值得注意的是,有时高层管理人员也会成为董事会成员。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。

Our most recent data indicates that insiders own some shares in MannKind Corporation. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around US$40m worth of shares (at current prices). If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling.

我们最近的数据表明,内部人士持有曼恩凯德生物医疗的部分股票。 这是一家相当大的公司,因此看到一些潜在的有意义的对齐通常是积极的。在这种情况下,他们持有约4000万美元的股票(按当前价格计算)。如果您想探索内部人士对齐的问题,可以点击这里查看内部人士是否有买入或卖出的行为。

General Public Ownership

一般大众所有权

With a 42% ownership, the general public, mostly comprising of individual investors, have some degree of sway over MannKind. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

公众持有42%的股份,大多数是个人投资者,对曼恩凯德生物医疗有一定程度的影响。虽然这种持股规模相当可观,但如果决策与其他大股东不一致,可能不足以改变公司政策。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand MannKind better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for MannKind you should be aware of, and 2 of them are a bit unpleasant.

考虑不同的股东群体总是值得的。但要更好地理解曼恩凯德生物医疗,我们需要考虑许多其他因素。 例如:我们发现曼恩凯德生物医疗有4个警告信号你应该注意,其中2个信号有点不愉快。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果您希望了解分析师在未来增长方面的预测,请务必不要错过这份免费报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发